Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Hold from Buy at Argus with analyst David Toung citing increased competition for the company's multiple sclerosis drugs, anticipating related sales to slow from the fourth quarter when results were boosted by "one-time factors." 2. Omnicom (OMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Steven Cahall downgraded Omnicom (OMC) to Sector Perform from Outperform and lowered his price target to $83 from $87. Cahall says the weaker than expected Q4 organic growth and soft FY18 outlook demonstrates the "opacity facing the industry". The analyst adds that he was hopeful to see more visibility into earnings growth by now. 3. Allison Transmission (ALSN) was downgraded to Sector Perform at RBC Capital and to Underweight from Neutral at JPMorgan. 4. Dr Pepper Snapple (DPS) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying the post-merger guidance "leaves little room for error" and the competitive environment in beverages is likely to "heat up." 5. Kimco Realty (KIM) downgraded to Neutral from Buy at BofA/Merrill with analyst Craig Schmidt saying he came away from earnings cautious on Kimco's weaker 2018 same-store NOI growth outlook of 1.25%-2%, the midpoint being the lowest since the recession, and 300M share repurchase program given the company's already high leverage and need to fund developments. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.